You most likely are aware that in December 2003, Congress enacted the MMA (Medicare Modernization Act). Since the majority of Medicare's payments for drugs provided in physician's offices (Part B) are for cancer treatment, it's prudent to evaluate how MMA will affect specialty pharmacy reimbursement and provider revenues.